Analytical Data
-
Gene name
Betacellulin
- Application
-
Biological Activity
The ED50 is <4>2.4691× 106 units/mg.
-
Alternative Names
rHuBetacellulin; BTC
-
Species
Human
-
Source
HEK293
-
Tag
Tag Free
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P35070
-
Expression Region
D32-Y111
-
Protein Length
Full Length of Betacellulin
-
Molecular Weight
15-18 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Betacellulin (BTC) is a member of the epidermal growth factor (EGF) family, which plays a crucial role in cell proliferation, differentiation, and survival. Research into BTC has gained significance due to its potential implications in diabetes treatment and pancreatic β-cell regeneration. Studies have shown that BTC can stimulate the proliferation of β-cells and enhance insulin secretion, making it a promising candidate for therapeutic interventions aimed at restoring β-cell function in diabetic patients. Additionally, BTC's ability to activate multiple signaling pathways, including the ErbB receptor family, highlights its intricate role in cellular communication and tissue repair. Investigations into the molecular mechanisms governing BTC's effects are ongoing, with a focus on understanding how it influences β-cell mass and function in both diabetic and healthy contexts. Furthermore, recombinant BTC protein has been developed for experimental use, enabling researchers to delve deeper into its biological activities and therapeutic potential. This line of research not only contributes to a better understanding of the pathophysiology of diabetes but also paves the way for novel regenerative therapies targeting β-cell dysfunction. As the prevalence of diabetes continues to rise globally, BTC emerges as a pivotal factor in the search for innovative treatments aimed at combating this chronic disease and improving patient outcomes.
